Skip to content
Interagency Autism Coordinating Committee (IACC)
Autism Research Database
Office of Autism Research Coordination (OARC)
 
Project Element Element Description

Project Title

Project Title

Early pharmacotherapy guided by biomarkers in autism (supplement)

Principal Investigator

Principal Investigator

Chugani, Diane

Description

Description

This is a supplement to project 5U01NS061264-05. This study is part of an Autism Centers of Excellence (ACE) Network. Previous research has shown that synthesis of the neurotransmitter serotonin is abnormal during critical periods of brain and synapse development in autistic children. The researchers hypothesize that one pharmacological approach to the treatment of autism is the use of serotonin agonists in children less than the age of six years. Following up on smaller pilot studies, this study is a randomized clinical trial of the serotonin agonist buspirone in a large group of young children with ASD. In this trial, researchers will test the safety and efficacy of buspirone in the treatment of core features of autism and associated behavioral dysfunction in young children with autism. Researchers will also employ a biomarker measure for serotonin synthesis capacity to assess patient differences in response to treatment. The researchers hypothesize that buspirone treatment effects on serotonin synthesis capacity will correlate with positive changes in social interaction, repetitive behavior, sensory dysfunction and anxiety. If buspirone is found to be safe and effective, it would represent a novel pharmacological treatment for core symptoms in ASDs.

Funder

Funder

National Institutes of Health

Fiscal Year Funding

Fiscal Year Funding

260000

Current Award Period

Current Award Period

2012-2013

Strategic Plan Question

Strategic Plan Question

Question 4: Which Treatments And Interventions Will Help?

Strategic Plan Objective

Strategic Plan Objective

Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4SF. Launch randomized controlled trials of interventions including biological signatures and other measures to predict response, and monitor quality of life and functional outcomes in each of the following groups: o Five trials in infants and toddlers by 2013. IACC Recommended Budget: $30,000,000 over 5 years. o Three trials in school-aged children and/or adolescents by 2013. IACC Recommended Budget: $18,000,000 over 5 years. o Three trials in adults by 2014. IACC Recommended Budget: $18,000,000 over 5 years.

Project Link

Project Link

Early pharmacotherapy guided by biomarkers in autism (supplement) (External web link)

Institution

Institution

Wayne State University

State/Country

State/Country

Michigan

Project Number

Project Number

3U01NS061264-05S1

Federal or Private?

Federal or Private?

Federal

Received ARRA Funding?

Received ARRA Funding?

No

History/Related Projects

History/Related Projects

ACE Network: Early pharmacotherapy guided by biomarkers in autism | 1498245 | 2011 | 5U01NS061264-04
ACE Network: Early pharmacotherapy guided by biomarkers in autism | 1996122 | 2012 | 5U01NS061264-05

 
Back to Top